title: A soluble deletion mutant of the human complement receptor type 1, which lacks the C4b binding site, is a selective inhibitor of the alternative complement pathway.
abstract: The human complement receptor type 1 (CR1, CD35), is a single-chain glycoprotein consisting of 30 repeating homologous protein domains known as short consensus repeats (SCR) followed by transmembrane and cytoplasmic domains. The SCR themselves, considered in groups of seven, form long homologous repeats (LHR) which have been designated LHR-A, -B, -C, and -D for the most common human allotype of CR1. A soluble deletion mutant of CR1 which lacks the first seven N-terminal SCR (LHR-A) as well as the transmembrane and cytoplasmic domains was produced and characterized. The resulting protein, designated sCR1[desLHR-A], lacks the C4b binding site found in LHR-A, but retains the two C3b binding sites found in LHR-B and -C, respectively. The functional activities of sCR1[desLHR-A] were quantitatively compared in vitro to those of soluble complement receptor type 1 (sCR1) which has been shown to retain all known functions of the native cell surface receptor. sCR1[desLHR-A] and sCR1 competed equally for the binding of dimeric C3b to erythrocyte CR1. sCR1[desLHR-A] and sCR1 were similar in their capacity to serve as a cofactor in the factor I-mediated degradation of the C3b and C4b alpha chains. sCR1[desLHR-A] and sCR1 were comparable in their capacity to inhibit erythrocyte lysis and anaphylatoxin production mediated by the alternative complement pathway. sCR1[desLHR-A], however, was significantly less effective an inhibitor of erythrocyte lysis and anaphylatoxin production than sCR1 under conditions which allow classical pathway activation. These results demonstrate sCR1[desLHR-A] to be a selective inhibitor of the alternative complement pathway in vitro.
authors.affiliation: T Cell Sciences, Inc., Needham, MA 02194, USA.
authors.forename: S M
authors.initials: SM
authors.lastname: Scesney
authors.forename: S C
authors.initials: SC
authors.lastname: Makrides
authors.forename: M L
authors.initials: ML
authors.lastname: Gosselin
authors.forename: P J
authors.initials: PJ
authors.lastname: Ford
authors.forename: B M
authors.initials: BM
authors.lastname: Andrews
authors.forename: E G
authors.initials: EG
authors.lastname: Hayman
authors.forename: H C
authors.initials: HC
authors.lastname: Marsh
mesh_terms: D001667:Binding, Competitive / Q000276:immunology; D003179:Complement C3b / Q000378:metabolism; D015935:Complement C4b / Q000172:deficiency* / Q000235:genetics*; D003169:Complement Inactivator Proteins / Q000235:genetics / Q000494:pharmacology*; D003170:Complement Pathway, Alternative / Q000187:drug effects / Q000235:genetics*; D003171:Complement Pathway, Classical / Q000187:drug effects; D006023:Glycoproteins; D006801:Humans; D009154:Mutation / Q000276:immunology*; D011485:Protein Binding / Q000276:immunology; D011951:Receptors, Complement / Q000737:chemistry / Q000172:deficiency* / Q000235:genetics* / Q000502:physiology*; D017384:Sequence Deletion / Q000276:immunology*; D012995:Solubility
chemical_list: D003169:Complement Inactivator Proteins; D006023:Glycoproteins; D011951:Receptors, Complement; D003179:Complement C3b; D015935:Complement C4b